Recursion Pharmaceuticals, Inc.
RXRX
$3.05
-$0.10-3.18%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -117.50M | -108.12M | -162.25M | -171.90M | -202.49M |
| Total Depreciation and Amortization | 19.67M | 19.48M | 21.04M | 23.85M | 19.33M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 24.54M | 31.89M | 50.15M | 36.48M | 57.05M |
| Change in Net Operating Assets | -7.81M | 10.68M | -26.30M | 35.15M | -5.85M |
| Cash from Operations | -81.10M | -46.07M | -117.36M | -76.42M | -131.96M |
| Capital Expenditure | -258.00K | -1.24M | -243.00K | -3.15M | -1.83M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | 0.00 | 0.00 | 0.00 | -4.44M |
| Other Investing Activities | -80.00K | 0.00 | -2.31M | -2.66M | -1.00M |
| Cash from Investing | -338.00K | -1.24M | -2.55M | -5.81M | -7.27M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -2.21M | -2.17M | -2.13M | -2.08M | -2.05M |
| Issuance of Common Stock | -- | 134.17M | 253.47M | 102.74M | 41.02M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.26M | 0.00 | 0.00 | -3.00M | 1.55M |
| Cash from Financing | -3.47M | 132.01M | 251.34M | 97.66M | 40.53M |
| Foreign Exchange rate Adjustments | -3.83M | 2.09M | 1.87M | 9.26M | 4.83M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -88.74M | 86.78M | 133.30M | 24.69M | -93.87M |